Almirall stock draws support from analysts and 2026 guidance
Published on 08/20/2026 at 11:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Almirall stock drew attention on August 20, 2026, after the Spanish drugmaker said first-half results stayed in line with estimates while analysts kept their support intact. Almirall (ES0157097017) reported net profit of €39.6 million for the first half of 2026, up 49.4%, on revenue of €605.6 million, up 7.5%.
First-half numbers
The earnings backdrop matters because the company is still guiding for full-year 2026 sales 9% to 12% above the prior year and EBITDA of €270 million to €290 million. That puts the first-half revenue base at €605.6 million against a higher full-year target, with profit growth outpacing sales growth in the period.
In market terms, the stock had fallen 19.1% in 2026 and had closed the prior session at €10.38, while the average analyst price target stood above €14.00. The gap is concrete: €10.38 against a target above €14.00 implies a double-digit spread that helps explain why the shares remain on watch despite the weak year-to-date tone.
What analysts see
The same coverage said the stock reached €13.60 in February and then lost momentum in the spring, leaving it at its lowest level in a year. That makes the 2026 setup more of a valuation and execution story than a pure trading bounce, with the 7.5% revenue rise and 49.4% profit increase serving as the key reported anchors.
A separate consensus snapshot showed Almirall at €10.46 on a three-month model view, versus a last price of €10.38, and valued the company at €2.32 billion. Those figures keep the debate centered on whether the company can convert a stronger first half into the top end of its sales and EBITDA range.
Dermatology remains central
Almirall's business is still led by dermatology in Europe, which the company and market commentary both point to as the main driver of the first-half performance. The core products tied to that franchise remain important because they link the first-half numbers to the full-year outlook rather than to a one-off quarter.
Almirall stock holds the range
As of August 20, 2026, the shares trade against a 2026 decline of 19.1%, a last close of €10.38, and a market value of €2.32 billion. The stock sits below the average target above €14.00, so the next test is whether execution can keep the first-half trend moving toward the €270 million to €290 million EBITDA goal.
Fact box
Company: Almirall SA
ISIN: ES0157097017
Ticker: ALM.MC
Exchange: BME
Market cap: €2.32 billion
Sector / Industry: Health Care / Pharmaceuticals
Index membership: IBEX 35
